Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$10.97 USD
+0.08 (0.73%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $10.97 0.00 (0.00%) 6:30 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVXL 10.97 +0.08(0.73%)
Will AVXL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVXL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVXL
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
AVXL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beat the Market the Zacks Way: Amgen, DRDGOLD, Anavex in Focus
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
Best Momentum Stocks to Buy for January 21st
Other News for AVXL
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August ...
Anavex Life Sciences (AVXL) Maintains 'Buy' Rating with $46 Target | AVXL Stock News
Anavex (AVXL) Reveals Promising Data for Alzheimer's Treatment
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral ...
Anavex announces precision medicine results of oral blarcamesine treatment